Comprehensive Evaluation of Quality Indicators: Analyzing the Dutch Breast Cancer Audit

Background: Quality indicators (QIs) are widely used to benchmark hospital performance and improve quality of care but are often based on expert opinion rather than data-driven assessment. This study aims to evaluate QIs, using a framework that assesses four criteria: Feasibility, discriminative ability, validity, and reliability. Methods: We used data from the Dutch breast cancer registry (NABON Breast Cancer Audit, NBCA) and included all surgically treated breast cancer patients in the Netherlands between 2021-2023. Eighteen QIs were evaluated. Feasibility was determined by QI numerator completeness, with >90% data availability considered feasible. Discriminative ability was assessed by between-hospital variation in QI scores, where an interquartile range (IQR) >10% indicated good discrimination. Validity was evaluated by the impact of case-mix adjustment and considered low when (pseudo-) R² <0.10. The (pseudo-)R² reflects the proportion of variance in QI scores explained by all case-mix variables in a regression model. Reliability was assessed by rankability, the proportion of between-hospital variation not due to chance and, therefore, explainable by quality of care. Rankability >75% was considered high. Results: After exclusion of one QI with feasibility <1%, feasibility ranged from 80.2%-100%, and 15 QIs were feasible. Overall, the IQR ranged from 1 to 36, with 8 QIs having an IQR higher than 10, indicating good discriminative ability. The (pseudo-)R² ranged from 0.01-0.53, with 11 QIs showing low case-mix impact. Rankability ranged from 0-69%, with none of the QIs having a high rankability. None of the QIs met all preset criteria, but six QIs met at least three out of four criteria. Conclusion: The QIs employed by the Dutch breast cancer registry fulfilled most criteria, but rankability is a concern and requires specific attention, especially for public reporting. Our results show the importance of considering feasibility, discriminative ability, validity, and reliability when evaluating QIs, and these should also be taken into account when developing new QIs.

Authors

Institutions

Publication Details

Journal
International Journal of Health Policy and Management
Published
2025-10-01
DOI
https://doi.org/10.34172/ijhpm.8943
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comprehensive Evaluation of Quality Indicators: Analyzing the Dutch Breast Cancer Audit

Hester F. Lingsma, Elfi M. Verheul, Margrietha van der Linde, Sabine Siesling et al.
International Journal of Health Policy and Management
Breast Cancer Treatment Studies
article

Comprehensive Evaluation of Quality Indicators: Analyzing the Dutch Breast Cancer Audit

Hester F. Lingsma, Elfi M. Verheul, Margrietha van der Linde, Sabine Siesling, Linetta B. Koppert, Elvira L. Vos
article en

Abstract

Background: Quality indicators (QIs) are widely used to benchmark hospital performance and improve quality of care but are often based on expert opinion rather than data-driven assessment. This study aims to evaluate QIs, using a framework that assesses four criteria: Feasibility, discriminative ability, validity, and reliability. Methods: We used data from the Dutch breast cancer registry (NABON Breast Cancer Audit, NBCA) and included all surgically treated breast cancer patients in the Netherlands between 2021-2023. Eighteen QIs were evaluated. Feasibility was determined by QI numerator completeness, with >90% data availability considered feasible. Discriminative ability was assessed by between-hospital variation in QI scores, where an interquartile range (IQR) >10% indicated good discrimination. Validity was evaluated by the impact of case-mix adjustment and considered low when (pseudo-) R² <0.10. The (pseudo-)R² reflects the proportion of variance in QI scores explained by all case-mix variables in a regression model. Reliability was assessed by rankability, the proportion of between-hospital variation not due to chance and, therefore, explainable by quality of care. Rankability >75% was considered high. Results: After exclusion of one QI with feasibility <1%, feasibility ranged from 80.2%-100%, and 15 QIs were feasible. Overall, the IQR ranged from 1 to 36, with 8 QIs having an IQR higher than 10, indicating good discriminative ability. The (pseudo-)R² ranged from 0.01-0.53, with 11 QIs showing low case-mix impact. Rankability ranged from 0-69%, with none of the QIs having a high rankability. None of the QIs met all preset criteria, but six QIs met at least three out of four criteria. Conclusion: The QIs employed by the Dutch breast cancer registry fulfilled most criteria, but rankability is a concern and requires specific attention, especially for public reporting. Our results show the importance of considering feasibility, discriminative ability, validity, and reliability when evaluating QIs, and these should also be taken into account when developing new QIs.

International Journal of Health Policy and ManagementVol. 14
Brown University (US), Rhode Island Hospital (US), Erasmus MC (NL), Dutch Institute for Clinical Auditing (NL), Netherlands Comprehensive Cancer Organisation (NL), Erasmus MC Cancer Institute (NL), University of Twente (NL)
Openalex Percentile: Top 53%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.